Iqymune

Human Normal Immunoglobulin, the active ingredient in Iqymune, is an immunoglobulin presented as a sterile intravenous solution for infusion use. It provides passive immunity by supplying normal human antibodies and is employed when patients have insufficient or defective immunoglobulin production, such as in primary or secondary immune deficiencies or autoimmune conditions.

GNH USA supplies Iqymune as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide and research institutions across Europe, Asia and the Americas with consistent quality.

Iqymune, a human normal immunoglobulin preparation, is used in several immune‑related conditions to restore antibody levels and modulate immune activity.

- Primary immunodeficiency diseases: restores protective antibody levels, reducing infection frequency. - Secondary immunodeficiency (e.g., chronic lymphocytic leukemia): supplements deficient IgG to improve immune competence. - Immune thrombocytopenic purpura (ITP): raises platelet counts by modulating auto‑antibody activity. - Kawasaki disease: reduces fever and coronary artery inflammation in children. - Guillain‑Barré syndrome: accelerates recovery by providing anti‑inflammatory antibodies.

Intravenous immunoglobulin therapy can be associated with a range of adverse reactions, from mild infusion‑related events to rare but serious complications.

Common Side Effects: - Headache - Fever or chills - Nausea or vomiting - Fatigue or malaise - Mild infusion site reactions (redness, swelling)

Serious or Rare Side Effects: - Anaphylactic or severe allergic reactions - Thromboembolic events (stroke, myocardial infarction) - Acute renal failure, especially with high‑osmolarity preparations - Aseptic meningitis - Hemolytic anemia - Severe thrombocytopenia

When using Iqymune, clinicians should observe several precautionary measures to minimise risks and ensure optimal therapeutic benefit. - Assess patient history: screen for IgA deficiency and previous severe reactions to immunoglobulins. - Monitor vital signs: observe blood pressure, temperature and respiratory status during infusion. - Adjust infusion rate: start slowly and increase gradually to reduce infusion‑related symptoms. - Review concomitant medications: anticoagulants and thrombotic risk factors may require dose modification. - Evaluate renal function: ensure adequate hydration and avoid nephrotoxic agents. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Human normal immunoglobulin can interact with other medicines, influencing efficacy or safety; awareness of key interactions guides safe co‑administration.

Major Interactions (Avoid): - Live vaccines: may be neutralised, reducing vaccine effectiveness. - High‑dose aspirin or other platelet inhibitors: increase risk of bleeding when combined with IVIG‑induced thrombocytopenia.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin, DOACs): IVIG may enhance pro‑coagulant activity, requiring INR monitoring. - Immunosuppressants (cyclosporine, tacrolimus): may alter drug levels; monitor therapeutic concentrations. - Diuretics and nephrotoxic drugs: heightened risk of renal impairment; assess renal function regularly.